Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart Failure
NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc. announced today that positive preclinical results of its novel cardioprotective agent, GP531, were reported in a poster presentation by Hani N. Sabbah, Ph.D., at the European Heart Failure Congress 2009 in Nice, France. The study was funded by PeriCor Therapeutics, Inc. and conducted by Dr. Sabbah and colleagues at the Division of Cardiovascular Medicine of the Henry Ford Health System, Detroit, Michigan. GP531 is an investigational drug under development by PeriCor Therapeutics under an Investigational New Drug (IND) application.
The study entitled "Intravenous GP531, an Adenosine Regulating Agent, Improves Left Ventricular Function in Dogs with Chronic Advanced Heart Failure" found that an acute intravenous infusion of GP531 at doses ranging from 3 mcg/kg/min to 300 mcg/kg/min significantly improves left ventricular (LV) systolic function. GP531 treatment, as compared to placebo, increased ejection fraction and decreased LV end-diastolic pressure, end-diastolic volume and end-systolic volume. This improvement in the heart's pumping ability was achieved without increasing heart rate or lowering blood pressure, and GP531 did not elicit de-novo ventricular arrhythmias, even at the highest doses.
GP531 is a second generation member of a novel new class of cardioprotective compounds known as adenosine regulating agents (ARAs). ARAs, including GP531, have demonstrated impressive cardioprotective activity in preclinical models of ischemia/reperfusion injury, but this pilot study is the first to evaluate an ARA in a model of heart failure. Dr. Sabbah stated, "This encouraging preclinical study strongly supports continued preclinical and clinical exploration of GP531 as an adjunct therapy for the treatment of acute heart failure syndromes. GP531
|SOURCE PeriCor Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved